



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
C07K 16/18 (2006.01) A61P 37/06 (2006.01)
C07K 16/46 (2006.01)

(21) International Application Number:

PCT/EP2024/083686

(22) International Filing Date:

27 November 2024 (27.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/603,406 28 November 2023 (28.11.2023) US
63/641,087 01 May 2024 (01.05.2024) US

(71) Applicants: **H. LUNDBECK A/S** [DK/DK]; Ottiliavej 9, 2500 Valby (DK). **APRILBIO CO., LTD.** [KR/KR]; B602, College of Biomedical Science Kangwon National University, 1 Kangwondaehak-gil, Gangwon-do 24341 (KR).

(72) Inventors: **NOÉ, Francesco, Mattia**; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). **ASENJO MARTINEZ, Andrea**; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). **CHA, Sang, Hoon**; 107-1204, 86, Useok-ro 101beon-gil, Chuncheon-si, Gangwon-do, Gangwon-do 24318 (KR). **SONG, Moo, Young**; Hyundai hilstate 114-302, 36, Gwongwang-ro 260beon-gil, Yeongtong-gu,

Suwon-si, Gyeonggi-do, Gyeonggi-do 16532 (KR). **EL-LIOT, Mark, Stephen, James**; c/o Lundbeck A/S Ottiliavej 9, 2500 Valby (DK).

(74) Agent: **H. LUNDBECK A/S**; Ottiliavej 9, 2500 Valby (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: FUSION PROTEINS FOR USE IN TREATMENT OF THYROID EYE DISEASE




FIG. 1

(57) Abstract: The present disclosure relates to methods of treatment of thyroid eye disease (TED) by administering a fusion protein, such as a fusion protein as defined herein, to subjects in need thereof. The disclosure provides treatment of pathophysiological parameters of TED, including both systemic and local pathophysiological parameters, whereby the disease is efficiently treated.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*